Cor Vasa 2010, 52(9):494-499 | DOI: 10.33678/cor.2010.135

Diastolic dysfunction and markers of collagen turnover

Jaroslav Meluzín1,*, Josef Tomandl2
1 1st Department of Internal Medicine/Cardioangiology, St. Anne's University Hospital, Masaryk University, Brno
2 Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic

The purpose of this paper is to summarize the current knowledge of the relationship of markers of collagen turnover to left ventricular (LV) diastolic dysfunction. There exists a strong relationship between the predominance of collagen synthesis over its degradation, myocardial fibrosis, and LV diastolic function. Some serum markers of collagen turnover were found to be practical surrogates of collagen content within the myocardium and indicators of the severity of LV diastolic dysfunction. However, the selection of optimal individual biomarkers for determination of various pathological clinical situations associated with disturbances in collagen turnover still requires further research.

Keywords: Diastolic dysfunction; Collagen; Biomarkers

Published: September 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Meluzín J, Tomandl J. Diastolic dysfunction and markers of collagen turnover. Cor Vasa. 2010;52(9):494-499. doi: 10.33678/cor.2010.135.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-2550. Go to original source... Go to PubMed...
    2. Spinale FG. Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res 2002;90:520-530. Go to original source... Go to PubMed...
    3. Lindsey ML, Mann DL, Entman ML, Spinale FG. Extracellular matrix remodeling following myocardial injury. Ann Med 2003;35:316-326. Go to original source... Go to PubMed...
    4. Weber KT, Sun Y, Tyagi SC, Cleutjens JPM. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994;26:279-292. Go to original source... Go to PubMed...
    5. Weber KT. Fibrosis and hypertensive disease. Curr Opin Cardiol 2000;15: 264-272. Go to original source... Go to PubMed...
    6. Querejeta R, Varo N, López B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000;101:1729-1735. Go to original source... Go to PubMed...
    7. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-1393. Go to original source... Go to PubMed...
    8. Miller A, Mujumdar V, Palmer L, et al. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens 2002;15:157-163. Go to original source... Go to PubMed...
    9. Joseph J, Washington A, Joseph L, et al. Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol 2002;283:H2567-H2574. Go to original source... Go to PubMed...
    10. Mujumdar VS, Aru GM, Tyagi SC. Induction of oxidative stress by homocysteine impairs endothelial function. J Cell Biochem 2001;82:491-500. Go to original source... Go to PubMed...
    11. Iraqi W, Rossignol P, Angioi M, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2009;119:2471-2479. Go to original source... Go to PubMed...
    12. Martos R, Baugh J, Ledwidge M, et al. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail 2009;11:191-197. Go to original source... Go to PubMed...
    13. Martos R, Baugh J, Ledwidge M, et al. Diastolic heart failure. Evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007;115:888-895. Go to original source... Go to PubMed...
    14. Mak GJ, Ledwidge MT, Watson ChJ, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009;54:1674-1682. Go to original source... Go to PubMed...
    15. Alla F, Kearney-Schwartz A, Radauceanu A, et al. Early changes in serum markers of extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur J Heart Fail 2006;8:147-153. Go to original source... Go to PubMed...
    16. Díez J, Panizo A, Gil MJ, et al. Serum markers of collagen type I metabolism in spontaneously hypertensive rats. Relation to myocardial fibrosis. Circulation 1996;93:1026-1032. Go to original source... Go to PubMed...
    17. Laviades C, Mayor G, Díez J. Treatment with lisinopril normalizes serum concentrations of procollagen type III amino-terminal peptide in patients with essential hypertension. Am J Hypertens 1994;7:52-58. Go to original source... Go to PubMed...
    18. López B, González A, Querejeta R, Díez J. The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens 2005;23:1445-1451. Go to original source... Go to PubMed...
    19. López B, Gonzáles A, Varo N, et al. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001;38:1222-1226. Go to original source... Go to PubMed...
    20. Wilson EM, Gunasinghe HR, Coker ML, et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Cardiac Fail 2002;8:390-398. Go to original source... Go to PubMed...
    21. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Bioch Bioph Acta 2000;1477:267-283. Go to original source... Go to PubMed...
    22. Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GYH. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension. Am J Hypertens 2004;17:770-774. Go to original source...
    23. McLean Timms P, Wright A, Maxwell P, et al. Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens 2002;15:269-272. Go to original source... Go to PubMed...
    24. Lindsay MM, Maxwell P, Dunn FG. TIMP-1. A marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002;40:136-141. Go to original source... Go to PubMed...
    25. Díez J, Querejeta R, López B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002;105:2512-2517. Go to original source... Go to PubMed...
    26. Querejeta R, López B, González A, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin. Relation to myocardial fibrosis. Circulation 2004;110:1263-1268. Go to original source... Go to PubMed...
    27. Díez J, Laviades C, Mayor G, et al. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 1995;91:1450-1456. Go to original source... Go to PubMed...
    28. Buckberg G, Hoffman JI, Mahajan A, et al. Cardiac mechanics revisited. The relationship of cardiac architecture to ventricular function. Circulation 2008;118:2571-2587. Go to original source... Go to PubMed...
    29. Kang SJ, Lim HS, Choi BJ, et al. Longitudinal strain and torsion assessed by two-dimensional speckle tracking correlate with the serum level of tissue inhibitor of matrix metalloproteinase-1, a marker of myocardial fibrosis, in patients with hypertension. J Am Soc Echocardiogr 2008;21:907-911. Go to original source... Go to PubMed...
    30. Poulsen SH, Andersen NH, Heickendorff L, Mogensen CE. Relation between plasma amino-terminal propeptide of procollagen type III and left ventricular longitudinal strain in essential hypertension. Heart 2005;91:624-629. Go to original source... Go to PubMed...
    31. Li-Saw-Hee FL, Edmunds E, Blann AD, et al. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000;75:43-47. Go to original source... Go to PubMed...
    32. Franz M, Berndt A, Altendorf-Hofmann A, et al. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail 2009;11:1057-1062. Go to original source... Go to PubMed...
    33. Nakahara T, Takata Y, Hirayama Y, et al. Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide. Circ J 2007;71:716-721. Go to original source... Go to PubMed...
    34. Walther T, Schubert A, Falk V, et al. Regression of left ventricular hypertrophy after surgical therapy for aortic stenosis is associated with changes in extracellular matrix gene expression. Circulation 2001;104(suppl I):I-54-I-58. Go to original source... Go to PubMed...
    35. Heymans S, Schroen B, Vermeersch P, et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005;112: 1136-1144. Go to original source... Go to PubMed...
    36. Nishikawa N, Yamamoto K, Sakata Y, et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 2003;57:766-774. Go to original source... Go to PubMed...
    37. Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases. Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089-2096. Go to original source... Go to PubMed...
    38. Sundström J, Evans JC, Benjamin EJ, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures. The Framingham Heart Study. Circulation 2004;109:2850-2856. Go to original source... Go to PubMed...
    39. Vorovich EE, Chuai S, Li M, et al. Comparison of matrix metalloproteinase 9 and brain natriuretic peptide as clinical biomarkers in chronic heart failure. Am Heart J 2008;155:992-997. Go to original source... Go to PubMed...
    40. Dhingra R, Pencina MJ, Schrader P, et al. Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community. Circulation 2009;119:1101-1107. Go to original source... Go to PubMed...
    41. Wang TJ, Larson MG, Benjamin EJ, et al. Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the community. Am Heart J 2007;154:291-297. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes